Search Results - "NAGAI, SHIGENORI E"

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition by Shimoi, Tatsunori, Nagai, Shigenori E., Yoshinami, Tetsuhiro, Takahashi, Masato, Arioka, Hitoshi, Ishihara, Mikiya, Kikawa, Yuichiro, Koizumi, Kei, Kondo, Naoto, Sagara, Yasuaki, Takada, Masahiro, Takano, Toshimi, Tsurutani, Junji, Naito, Yoichi, Nakamura, Rikiya, Hattori, Masaya, Hara, Fimikata, Hayashi, Naoki, Mizuno, Toshiro, Miyashita, Minoru, Yamashita, Nami, Yamanaka, Takashi, Saji, Shigehira, Iwata, Hiroji, Toyama, Tatsuya

“…Purpose We present the English version of The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer, 2018…”
Get full text

Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer by Tozuka, Katsunori, Wongsirisin, Pattama, Nagai, Shigenori E., Kobayashi, Yasuhito, Kanno, Miki, Kubo, Kazuyuki, Takai, Ken, Inoue, Kenichi, Matsumoto, Hiroshi, Shimizu, Yoshihito, Suganuma, Masami

“…To understand the mechanism underlying metastasis, identification of a mechanism-based and common biomarker for circulating tumour cells (CTCs) in heterogenous…”
Get full text

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial by Masuda, Norikazu, Bando, Hiroko, Yamanaka, Takashi, Kadoya, Takayuki, Takahashi, Masato, Nagai, Shigenori E., Ohtani, Shoichiro, Aruga, Tomoyuki, Suzuki, Eiji, Kikawa, Yuichiro, Yasojima, Hiroyuki, Kasai, Hiroi, Ishiguro, Hiroshi, Kawabata, Hidetaka, Morita, Satoshi, Haga, Hironori, Kataoka, Tatsuki R., Uozumi, Ryuji, Ohno, Shinji, Toi, Masakazu

“…Purpose To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Methods Patients in…”
Get full text

Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study) by Kimizuka, Kei, Inoue, Kenichi, Nagai, Shigenori E., Saito, Tsuyoshi, Nakano, Satoko, Futsuhara, Kazushige, Yamada, Hirofumi, Kaneko, Shiori, Sakurai, Takashi, Hata, Satoshi, Kurosumi, Masafumi

“…Background: Fulvestrant 500 mg has been an option for endocrine therapy for advanced or recurrent breast cancer after prior endocrine treatment since November…”
Get full text

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition by Shimoi, Tatsunori, Nagai, Shigenori E., Yoshinami, Tetsuhiro, Takahashi, Masato, Arioka, Hitoshi, Ishihara, Mikiya, Kikawa, Yuichiro, Koizumi, Kei, Kondo, Naoto, Sagara, Yasuaki, Takada, Masahiro, Takano, Toshimi, Tsurutani, Junji, Naito, Yoichi, Nakamura, Rikiya, Hattori, Masaya, Hara, Fimikata, Hayashi, Naoki, Mizuno, Toshiro, Miyashita, Minoru, Yamashita, Nami, Yamanaka, Takashi, Saji, Shigehira, Iwata, Hiroji, Toyama, Tatsuya

“…A correction to this paper has been published: https://doi.org/10.1007/s12282-021-01252-x…”
Get full text

Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer by HAYASHI, YUJI, TAKEI, HIROYUKI, NOZU, SATOSHI, TOCHIGI, YOSHIHIRO, ICHIKAWA, AKIHIRO, KOBAYASHI, NAOKI, KUROSUMI, MASAFUMI, INOUE, KENICHI, YOSHIDA, TAKASHI, NAGAI, SHIGENORI E, OBA, HANAKO, TABEI, TOSHIO, HORIGUCHI, JUN, TAKEYOSHI, IZUMI

“…In the present study, clinical tumor response following neoadjuvant chemotherapy (NAC) was diagnosed by magnetic resonance imaging (MRI) and…”
Get full text

Prognostic significance of the number of axillary lymph nodes examined in breast cancer by Nagai, Shigenori E

Get more information

A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer by Yamada, Hirofumi, Inoue, Kenichi, Nagai, Shigenori E., Nakai, Maki, Arisawa, Fumio, Ueda, Hiroyuki, Saito, Tsuyoshi, Ninomiya, Jun, Kuroda, Toru, Sakurai, Takashi, Kodama, Hitomi, Kimizuka, Kei, Hata, Satoshi, Kai, Toshihiro, Kurosumi, Masafumi, investigators, for the SBCCSG

“…Objective: Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients…”
Get full text

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients by Fujiwara, Yasuhiro, Mukai, Hirofumi, Saeki, Toshiaki, Ro, Jungsil, Lin, Yung-Chang, Nagai, Shigenori E., Lee, Keun Seok, Watanabe, Junichiro, Ohtani, Shoichiro, Kim, Sung Bae, Kuroi, Katsumasa, Tsugawa, Koichiro, Tokuda, Yutaka, Iwata, Hiroji, Park, Yeon Hee, Yang, Youngsen, Nambu, Yoshihiro

“…Background NK105 is a novel nanoparticle drug delivery formulation that encapsulates paclitaxel (PTX) in polymeric micelles. We conducted an open-label phase…”
Get full text

Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition by Yoshinami, Tetsuhiro, Koizumi, Kei, Nagai, Shigenori E., Toyama, Tatsuya, Iwata, Hiroji

“…Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles may enhance efficacy. Dose-dense chemotherapy, which is adopted…”
Get full text

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study by Yoshinami, Tetsuhiro, Nagai, Shigenori E., Hattori, Masaya, Okamura, Takuho, Watanabe, Kenichi, Nakayama, Takahiro, Masuda, Hiroko, Tsuneizumi, Michiko, Takabatake, Daisuke, Harao, Michiko, Yoshino, Hiroshi, Mori, Natsuko, Yasojima, Hiroyuki, Oshiro, Chiya, Iwase, Madoka, Yamaguchi, Miki, Sangai, Takafumi, Kosaka, Nobuyoshi, Tajima, Kentaro, Masuda, Norikazu

“…Background A recent large real-world study conducted in the United States reported the effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2−…”
Get full text

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition by Terada, Mitsuo, Ito, Aki, Kikawa, Yuichiro, Koizumi, Kei, Naito, Yoichi, Shimoi, Tatsunori, Ishihara, Mikiya, Yamanaka, Takashi, Ozaki, Yukinori, Hara, Fumikata, Nakamura, Rikiya, Hattori, Masaya, Miyashita, Minoru, Kondo, Naoto, Yoshinami, Tetsuhiro, Takada, Masahiro, Matsumoto, Koji, Narui, Kazukata, Sasada, Shinsuke, Iwamoto, Takayuki, Hosoda, Mitsuchika, Takano, Yuko, Oba, Takaaki, Sakai, Hitomi, Murakami, Akari, Higuchi, Toru, Tsuchida, Junko, Tanabe, Yuko, Shigechi, Tomoko, Tokuda, Emi, Harao, Michiko, Kashiwagi, Shinichiro, Mase, Junichi, Watanabe, Junichiro, Nagai, Shigenori E., Yamauchi, Chikako, Yamamoto, Yutaka, Iwata, Hiroji, Saji, Shigehira, Toyama, Tatsuya

“…The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a…”
Get full text

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study by Takahashi, Masato, Ohtani, Shoichiro, Nagai, Shigenori E., Takashima, Seiki, Yamaguchi, Miki, Tsuneizumi, Michiko, Komoike, Yoshifumi, Osako, Tomofumi, Ito, Yoshinori, Ikeda, Masahiko, Ishida, Kazushige, Nakayama, Takahiro, Takashima, Tsutomu, Asakawa, Takashi, Matsumoto, Sho, Shimizu, Daisuke, Masuda, Norikazu

“…Purpose In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese…”
Get full text

A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer by Hirofumi Yamada, Kenichi Inoue, Shigenori E. Nagai, Maki Nakai, Fumio Arisawa, Hiroyuki Ueda, Tsuyoshi Saito, Jun Ninomiya, Toru Kuroda, Takashi Sakurai, Hitomi Kodama, Kei Kimizuka, Satoshi Hata, Toshihiro Kai, Masafumi Kurosumi, for the SBCCSG investigators

“…Objective: Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients…”
Get full text

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer by Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Maeda, Patricia, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, Schwartzberg, Lee S.

“…A previous randomized phase II trial suggested that sorafenib might enhance the efficacy of capecitabine in patients with metastatic breast cancer. However, in…”
Get full text

TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study by Inoue, Kenichi, Nagai, Shigenori E., Saito, Tsuyoshi, Sakurai, Takashi, Kimizuka, Kei, Yamada, Hirofumi, Kuroda, Toru, Hata, Satoshi, Yamazaki, Yasuo, Kojima, Masato, Futsuhara, Kazushige

“…Summary Purpose We examined the feasibility, efficacy, and safety of TS-1 add-on therapy (TAT) in Japanese patients with triple-negative breast caner (TNBC)…”
Get full text

Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B by Matsumoto, Koji, Nishimura, Meiko, Ozaki, Yukinori, Futamura, Manabu, Miyaki, Toshikio, Tsurutani, Junji, Imoto, Shigeru, Doi, Mihoko, Tokunaga, Shinya, Aogi, Kenjiro, Yoshimura, Kenichi, Okada, Hideaki, Sagara, Yasuaki, Baba, Motoi, Nagai, Shigenori E., Takano, Toshimi

“…Abstract only e12022 Background: PCP is rare complication of ddAC-ddP. DEX is plausible risk factor for PCP. Dose and duration of DEX against CINV is changing…”
Get full text

Values of tumor-infiltrating lymphocytes (TILs), CD8+ TILs, and PDL-1 for predicting pathological complete response and prognosis in HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab by Kurozumi, Sasagu, Inoue, Kenichi, Kurosumi, Masafumi, Matsumoto, Hiroshi, Hayashi, Yuji, Tozuka, Katsunori, Kubo, Kazuyuki, Komatsu, Kei, Takai, Ken, Nagai, Shigenori E., Oba, Hanako, Horiguchi, Jun

“…Abstract only…”
Get full text

Impact of combining PgR score and original preoperative endocrine prognostic index (PEPI) score as a prognostic factor of neoadjuvant endocrine therapy using exemestane in postmenopausal ER-positive/HER2-negative breast cancer by Kurozumi, Sasagu, Matsumoto, Hiroshi, Tozuka, Katsunori, Hayashi, Yuji, Inoue, Kenichi, Nagai, Shigenori E., Oba, Hanako, Horiguchi, Jun, Takeyoshi, Izumi, Kurosumi, Masafumi

“…Abstract only…”
Get full text

Feasibility study of TS-1 additional therapy for the triple-negative breast cancer received neoadjuvant or adjuvant chemotherapy (SBCCSG14) by Futsuhara, Kazushige, Inoue, Kenichi, Nagai, Shigenori E., Saito, Tsuyoshi, Sakurai, Takashi, Kimizuka, Kei, Kurozumi, Masafumi, Tabei, Toshio, Yamada, Hirofumi, Kojima, Masato, Hata, Satoshi, Yamazaki, Yasuo

“…Abstract only 162 Background: Prospective randomized clinical trials have demonstrated a significant advantage from postoperative adjuvant chemotherapy for…”
Get full text